Permeability of novel 4′-N-substituted (aminomethyl) benzoate-7-substituted nicotinic acid ester derivatives of scutellarein in Caco-2 cells and in an in vitro model of the blood-brain barrier

Ou, Yu; Luo, Min; Dong, Yong‐Xi; Su, Hang; Fu, Xiao‐Zhong; Cha, Yu-Feng; Zhang, Shun; Zhao, Yong‐Long; Li, Yongjun; Wang, Yonglin

doi:10.1007/s00044-016-1659-y

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven active compounds of FA were obtained, such as isomerancin, meranzin, prangenin, bergapten, 5, 6, 7, 4′tetramethoxyflavone, 3′, 4′, 7, 8-tetramethoxyflavone, and Scutellarein. Scutellarein has a good permeability in the BBB model in vitro, has the ability to improve BBB dysfunction, and treats stroke, Alzheimer's disease, and other central nervous system diseases [27,28]. Bergapten has extremely high bioavailability, can cross the BBB, protect nerves, and treat brain diseases, and it is a potential candidate as antidepressant drug [29].…”

Section: Screening Of the Active Components In Famentioning

confidence: 99%

Based on UPLC-Q-TOF-MS/MS, Systematic Network Pharmacology, and Molecular Docking to Explore the Potential Mechanism of Fructus Aurantii for Major Depression Disorder

Xie

Liu

Zheng

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Major Depression Disorder (MDD) is a common mental disease that has become one of the world’s major medical diseases. Currently, the Fructus Aurantii (FA) has been widely used to treat depression. However, the active substance ingredients and potential mechanisms of the shell antidepression have not yet been clarified. Method. First, we used ultraperformance liquid chromatography-quadrupole/time-of-flight tandem mass (UPLC-QTOF-MS/MS) technology to identify the chemical composition of the FA. Then, it is predicted for active ingredients, pharmaceutical disease target screening by DiscoveryStudio 2016 (DS), Metascape, and other databases, PPI network diagram, and FC core pathway. Finally, the system network pharmacology results are verified by molecular contact verification. Results. Forty-six compounds in FA were identified, and twelve active ingredients were determined. Various database information, PPI network analysis of 41 intersections, and 20 core targets including DRD2, MTOR, FASP3, and PIK3P1 were integrated. Finally, the MDD treatment is indicated by molecular docking, and the most relevant potential signal pathway is the PI3K-Akt signaling pathway.

show abstract

Section: Screening Of the Active Components In Famentioning

confidence: 99%